FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kimberly Chianese-Bullock

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Treatment Outcome

Anatomy

CD8-Positive T-Lymphocytes

Co-author Network

Publications

TOP 3
Joshua M Judge; Anneke T Schroen; Kimberly A Chianese-Bullock; Craig L Slingluff
Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial.
Craig L Slingluff; Mark E Smolkin; Margaret von Mehren; Kimberly A Chianese-Bullock; Naomi B Haas; Gina R Petroni; Merrick I Ross; William W Grosh
Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
Walter C Olson; Mark E Smolkin; Erin M Farris; Robyn J Fink; Andrea R Czarkowski; Jonathan H Fink; Kimberly A Chianese-Bullock; Craig L Slingluff
Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kimberly Chianese-Bullock (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Joshua M Judge; Anneke T Schroen; Kimberly A Chianese-Bullock; Craig L Slingluff
Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial.
Clinical trials (London, England) 2013;10(1):143-50.
2011: Craig L Slingluff; Mark E Smolkin; Margaret von Mehren; Kimberly A Chianese-Bullock; Naomi B Haas; Gina R Petroni; Merrick I Ross; William W Grosh
Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(21):2924-32.
2011: Walter C Olson; Mark E Smolkin; Erin M Farris; Robyn J Fink; Andrea R Czarkowski; Jonathan H Fink; Kimberly A Chianese-Bullock; Craig L Slingluff
Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function.
Journal of translational medicine 2011;9():26.
2010: Craig L Slingluff; Gina R Petroni; Mark E Smolkin; Kimberly A Chianese-Bullock; Kelly Smith; Cheryl Murphy; Nadedja Galeassi; Patrice Y Neese; William W Grosh; Carmel J Nail; Merrick Ross; Margaret von Mehren; Naomi Haas; Marc E Boisvert; John M Kirkwood
Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(6):630-8.
2009: Craig L Slingluff; Gina R Petroni; Walter C Olson; Mark E Smolkin; Merrick I Ross; Naomi B Haas; William W Grosh; Marc E Boisvert; John M Kirkwood; Kimberly A Chianese-Bullock
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):7036-44.
2009: Kimberly A Chianese-Bullock; Sarah T Lewis; Nicholas E Sherman; John D Shannon; Craig L Slingluff
Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.
Vaccine 2009;27(11):1764-70.
2008: Craig L Slingluff; Gina R Petroni; Walter Olson; Andrea Czarkowski; William W Grosh; Mark E Smolkin; Kimberly A Chianese-Bullock; Patrice Y Neese; Donna H Deacon; Carmel Nail; Priscilla Merrill; Robyn Fink; James W Patterson; Patrice K Rehm
Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4973-80.
2008: Kimberly A Chianese-Bullock; William P Irvin; Gina R Petroni; Cheryl Murphy; Mark E Smolkin; Walter C Olson; Elizabeth Coleman; Scott A Boerner; Carmel J Nail; Patrice Y Neese; Arlene Yuan; Kevin T Hogan; Craig L Slingluff
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(4):420-30.
2008: Donna H Deacon; Kevin T Hogan; Erin M Swanson; Kimberly A Chianese-Bullock; Chadrick E Denlinger; Andrea R Czarkowski; Randy S Schrecengost; James W Patterson; Mark W Teague; Craig L Slingluff
The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines.
BMC cancer 2008;8():360.
2007: Craig L Slingluff; Gina R Petroni; Kimberly A Chianese-Bullock; Mark E Smolkin; Sarah Hibbitts; Cheryl Murphy; Naomi Johansen; William W Grosh; Galina V Yamshchikov; Patrice Y Neese; James W Patterson; Robyn Fink; Patrice K Rehm
Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6386-95.
2006: Craig L Slingluff; Kimberly A Chianese-Bullock; Timothy N J Bullock; William W Grosh; David W Mullins; Lisa Nichols; Walter Olson; Gina R Petroni; Mark E Smolkin; Victor H Engelhard
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Advances in immunology 2006;90():243-95.
2005: Kimberly A Chianese-Bullock; Elizabeth M H Woodson; Huimin Tao; Scott A Boerner; Mark E Smolkin; William W Grosh; Patrice Y Neese; Priscilla Merrill; Gina R Petroni; Craig L Slingluff
Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(4):412-9.
2005: Kimberly A Chianese-Bullock; Jennifer Ghith; Courtney F Garbee; Sarah Hibbitts; Cheryl Murphy; Galina V Yamshchikov; Gina R Petroni; Eric A Bissonette; Patrice Y Neese; William W Grosh; Priscilla Merrill; Robyn Fink; Elizabeth M H Woodson; Catherine J Wiernasz; James W Patterson; Craig L Slingluff
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(5):3080-6.
2004: Craig L Slingluff; Gina R Petroni; Galina V Yamshchikov; Sarah Hibbitts; William W Grosh; Kimberly A Chianese-Bullock; Eric A Bissonette; Donna L Barnd; Donna H Deacon; James W Patterson; Jaysheree Parekh; Patrice Y Neese; Elizabeth M H Woodson; Catherine J Wiernasz; Priscilla Merrill
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(22):4474-85.
2004: Lee W Thompson; Courtney F Garbee; Sarah Hibbitts; Laurence H Brinckerhoff; Richard A Pierce; Kimberly A Chianese-Bullock; Donna H Deacon; Victor H Engelhard; Craig L Slingluff
Competition among peptides in melanoma vaccines for binding to MHC molecules.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(6):425-31.
2004: Elizabeth M H Woodson; Kimberly A Chianese-Bullock; Catherine J Wiernasz; Eric A Bissonette; William W Grosh; Patrice Y Neese; Priscilla Merrill; Donna L Barnd; Gina R Petroni; Craig L Slingluff
Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(5):380-8.
2003: Craig L Slingluff; Gina R Petroni; Galina V Yamshchikov; Donna L Barnd; Shannon Eastham; Holly Galavotti; James W Patterson; Donna H Deacon; Sarah Hibbitts; David Teates; Patrice Y Neese; William W Grosh; Kimberly A Chianese-Bullock; Elizabeth M H Woodson; Catherine J Wiernasz; Priscilla Merrill; Jennifer Gibson; Maureen Ross; Victor H Engelhard
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(21):4016-26.
2002: Carolina Soguero; Myungsoo Joo; Kimberly A Chianese-Bullock; Duong Tony Nguyen; Kenneth Tung; Young S Hahn
Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model.
Journal of virology 2002;76(18):9345-54.
2000: DJ Kittlesen; Kimberly A Chianese-Bullock; Zhi Qiang Yao; Thomas J Braciale; Young S Hahn
Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation.
The Journal of clinical investigation 2000;106(10):1239-49.